FDA boost lifts Moderna shares: Can MRNA extend rally?
Moderna shares moved higher after the FDA released briefing documents related to the company's mFlu influenza vaccine, which investors interpreted as a positive signal for the potential approval of the treatment.
The primary catalyst in recent days has been the FDA materials published ahead of the advisory committee meeting on mFlu. Regulators did not highlight any major concerns regarding Moderna's application, leading the market to view the update as a reduction in regulatory risk.
For years, Moderna was largely perceived as a company dependent on its COVID-19 vaccine. However, the potential launch of an influenza vaccine could become one of the company's key revenue drivers in the coming years.
Another catalyst is Science Day, scheduled for June 25. Investors hope to receive new data on Moderna's oncology programs, combination vaccines, and other initiatives based on its mRNA platform.
Technical picture points to further upside
As noted in previous analysis, a breakout above the 50-day simple moving average (SMA) triggered a strong bullish move toward $56.25.
The stock successfully cleared the $50 level on elevated trading volume, increasing confidence in the continuation of the upward trend.
The next level Moderna is likely to test is the local high at $59.55. If the stock breaks above this level on strong volume, the probability of a move toward $65 increases significantly.
However, investors should remain cautious and keep potential risks in mind. On June 16, MRNA failed to establish itself above the $56.25 resistance level. As a result, the nearest support area around $52 remains important.
Market begins to revalue Moderna's business
Just a few years ago, Moderna was viewed as a company almost entirely dependent on COVID-19 vaccine sales. Today, that perception is gradually changing.
The company continues to advance its combination COVID-19 and influenza vaccine program, while also developing a personalized cancer vaccine in partnership with Merck.
This is why the current rally appears more fundamentally justified than previous rebounds. Investors are increasingly beginning to view Moderna as a diversified biotechnology company with multiple potential revenue streams rather than simply a former pandemic beneficiary.
Latest Moderna News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
